"1"^^ . "Suppl 4" . . . . "The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses"@en . "2"^^ . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "skin fungal infections; topical treatment; antimycotics; imidazoles; corticosteroid; inflammation"@en . "RIV/00216208:11120/08:00000863!RIV09-MSM-11120___" . . . . "V\u00FDhody topick\u00E9 kombina\u010Dn\u00ED terapie v l\u00E9\u010Db\u011B z\u00E1n\u011Btliv\u00FDch dermatomyk\u00F3z"@cs . "11"^^ . . . "[7A432326BF9E]" . "The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses" . "Mycoses" . "RIV/00216208:11120/08:00000863" . "000259370100003" . . . . . "Friedrich, Markus" . "The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses" . "51" . "Dermatomycoses are contagious superficial skin fungal infections, which are highly prevalent in developed and developing countries, and manifest on glabrous skin as an annular scaly lesion with a variable inflammatory component. Mostly, dermatomycoses of glabrous skin are treated with topical antifungal agents, such as imidazoles and allylamines. Clinical studies show, however, that the addition of a topical corticosteroid to imidazole therapy increases the bioavailability and prolongs the activity of the antimycotic in the skin, while rapidly reducing inflammatory symptoms, improving mycological cure rate and provides antifungal protection against skin reinfection for some weeks after therapy"@en . "355024" . "0933-7407" . . "S" . "V\u00FDhody topick\u00E9 kombina\u010Dn\u00ED terapie v l\u00E9\u010Db\u011B z\u00E1n\u011Btliv\u00FDch dermatomyk\u00F3z"@cs . "Havl\u00ED\u010Dkov\u00E1, Blanka" . . "Dermatomycoses are contagious superficial skin fungal infections, which are highly prevalent in developed and developing countries, and manifest on glabrous skin as an annular scaly lesion with a variable inflammatory component. Mostly, dermatomycoses of glabrous skin are treated with topical antifungal agents, such as imidazoles and allylamines. Clinical studies show, however, that the addition of a topical corticosteroid to imidazole therapy increases the bioavailability and prolongs the activity of the antimycotic in the skin, while rapidly reducing inflammatory symptoms, improving mycological cure rate and provides antifungal protection against skin reinfection for some weeks after therapy" . . "Dermatomyk\u00F3zy jsou naka\u017Eliv\u00E9 povrchov\u00E9 pl\u00EDs\u0148ov\u00E9 infekce k\u016F\u017Ee, kter\u00E9 jsou vysoce roz\u0161\u00ED\u0159en\u00E9 ve vysp\u011Bl\u00FDch i rozvojov\u00FDch zem\u00EDch a manifestuj\u00ED se na k\u016F\u017Ei jako anul\u00E1rn\u00ED \u0161upinat\u00E1 lo\u017Eiska s variabiln\u00ED z\u00E1n\u011Btlivou slo\u017Ekou. Ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F jsou povrchov\u00E9 mykotick\u00E9 infekce k\u016F\u017Ee l\u00E9\u010Deny lok\u00E1ln\u00EDmi antimykotiky, nap\u0159. ze skupiny imidazol\u016F a allylamin\u016F. Klinick\u00E9 studie nicm\u00E9n\u011B ukazuj\u00ED, \u017Ee kombinace lok\u00E1ln\u00EDho kortikoidu s imidazolov\u00FDm antimykotick\u00FDm p\u0159\u00EDpravkem zvy\u0161uje dostupnost a prodlu\u017Euje aktivitu antimykotika v k\u016F\u017Ei, d\u00E1le pak v\u00FDrazn\u011B redukuje z\u00E1n\u011Btliv\u00E9 projevy na k\u016F\u017Ei, zlep\u0161uje hojen\u00ED a tak\u00E9 poskytuje protipl\u00EDs\u0148ovou ochranu proti reinfekci k\u016F\u017Ee na n\u011Bkolik t\u00FDdn\u016F po skon\u010Den\u00ED terapie"@cs . "The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses"@en . "11120" . . .